Compare Heron Therapeutics Inc (HRTX) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.87 (market cap $2.03B). The key difference: Direxion Daily 20 Year Treasury Bull 3X Shares is far larger — about 29.8× Heron Therapeutics Inc's market cap, and Direxion Daily 20 Year Treasury Bull 3X Shares is more actively traded (12,241,664 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| HRTX | TMF | |
|---|---|---|
Market Cap | $68.01M | $2.03B |
Volume | 1,891,941 | 12,241,664 |
Sector | Health | Fixed Income |
52-Week High | $1.49 | $44.14 |
52-Week Low | $0.27 | $25.19 |
Typical Hold Time | 35 Days | 28 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
TMF trades at $25.23, down 0.51% with bearish technical signals from moving averages. The ETF saw increased trading volume of 5.2 million shares, indicating heightened investor interest. Key support sits at $24-25 while resistance levels are at $25-26. RSI readings below 20 suggest potential oversold conditions despite the bearish trend.
As a leveraged Treasury ETF, TMF faces interest rate sensitivity and market volatility risks. The bearish technical outlook and Federal Reserve policy uncertainty create headwinds, though oversold conditions may present tactical opportunities for investors anticipating rate cuts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
